[Clinical application of enzyme inhibitors--hematologic malignancies].
Ueda
T
T
First Department of Medicine, Fukui Medical School.
Nakamura
T
T
D003561:Cytarabine / Q000494:pharmacology / Q000627:therapeutic use*; D004264:DNA Topoisomerases, Type I; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D005047:Etoposide / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D015122:Mercaptopurine / Q000494:pharmacology / Q000627:therapeutic use; D008727:Methotrexate / Q000494:pharmacology / Q000627:therapeutic use; D011687:Purines / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000037:antagonists & inhibitors; D013866:Thioguanine / Q000494:pharmacology / Q000627:therapeutic use; D059004:Topoisomerase I Inhibitors; D000093542:Gemcitabine
D011687:Purines; D011743:Pyrimidines; D059004:Topoisomerase I Inhibitors; D003561:Cytarabine; D003841:Deoxycytidine; D005047:Etoposide; D015122:Mercaptopurine; D004264:DNA Topoisomerases, Type I; D013866:Thioguanine; D008727:Methotrexate; D000093542:Gemcitabine